Fig. 7
PaWOX2 inhibits proliferation and promotes maturation. Embryogenic tissue from the control and three 35S:WOX2i lines were re-suspended in liquid medium after pre-maturation treatment and thereafter plated out as a thin layer on solidified maturation medium. Data are presented as means ± SE of three biological replicates. a The maturation process was examined for 14 days on maturation medium. The areas in the dark squares are presented in higher magnification in the inserts. Examples of proliferating tissues and MEs are denoted by arrows (↑, proliferating tissue. ⬆, ME). In the control culture: day 1 and 3, note the low proliferation of embryogenic tissue; day 6, note that LE1s have developed; day 10 and 14, note that MEs have developed. In the 35:WOX2i line: day 1 and 3, note the high proliferation of embryogenic tissue compared to the control; day 6, note that the embryogenic tissue continued to proliferate and LE1s had developed; day 10 to 14, note that the embryogenic tissue continued to proliferate and only a few MEs developed. em, embryonal mass; s, suspensor. Bar, 5 mm. b Number of MEs/gram tissue from the control and three 35S:WOX2i lines after seven weeks on maturation medium (Additional file 10: Table S6). Asterisks indicate significant differences in the number of MEs between the control and the transgenic lines (one tail t-test, p < 0.05). c Number of MEs/gram tissue formed in the control and line XVE-WOX2i.12 after seven weeks on maturation medium (Additional file 11: Table S7). a: Non-induced cultures; b: Early-induced cultures were treated with β-estradiol from the first week on maturation medium; c: Late-induced cultures were treated with β-estradiol from the third week on maturation medium. Asterisk indicates significant difference in the number of MEs in line XVE-WOX2i.12, between non-induced (a), and induced from the first week on maturation medium (b) (one tail t-test, p < 0.05)